PEPTONIC medical AB (publ) (XSAT:PMED)
Sweden · Delayed Price · Currency is SEK 0.0600
0.00 (0.00%)
At close: Jan 31, 2024
PEPTONIC medical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10.95 | 14.79 | 26.89 | 37.12 | 43.63 | 31.64 | |
Revenue Growth | -44.89% | -45.01% | -27.55% | -14.93% | 37.90% | 48.68% |
Cost of Revenue | 5.08 | 4.84 | 11.73 | 20.82 | 20.24 | 12.57 |
Gross Profit | 5.88 | 9.95 | 15.16 | 16.3 | 23.4 | 19.07 |
Selling, General & Admin | 29.35 | 35.3 | 56.72 | 52.28 | 56.11 | 65.12 |
Other Operating Expenses | -11.48 | -11.65 | -7.64 | -1.06 | -2.6 | 0.61 |
Operating Expenses | 23.62 | 29.4 | 73.81 | 57.48 | 57 | 92.79 |
Operating Income | -17.74 | -19.45 | -58.65 | -41.19 | -33.61 | -73.72 |
Interest Expense | -3.51 | -3.09 | -1.41 | -2.32 | -5.56 | -0.07 |
Interest & Investment Income | 0.05 | 0.05 | 0.03 | 0.92 | 2.31 | 0.1 |
Other Non Operating Income (Expenses) | 0.2 | 0 | - | 0 | - | -0 |
Pretax Income | -21 | -22.5 | -60.03 | -42.59 | -36.86 | -73.69 |
Net Income | -21 | -22.5 | -60.03 | -42.59 | -36.86 | -73.69 |
Net Income to Common | -21 | -22.5 | -60.03 | -42.59 | -36.86 | -73.69 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 8,425 | 3,600 | 1,535 | 243 | 192 |
Shares Outstanding (Diluted) | - | 8,425 | 3,600 | 1,535 | 243 | 192 |
Shares Change | - | 134.00% | 134.57% | 532.29% | 26.67% | 17.63% |
EPS (Basic) | - | -0.00 | -0.02 | -0.03 | -0.15 | -0.38 |
EPS (Diluted) | - | -0.00 | -0.02 | -0.03 | -0.15 | -0.38 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | - | -37.56 | -34.45 | -40.22 | -43.36 |
Free Cash Flow Per Share | - | - | -0.01 | -0.02 | -0.17 | -0.23 |
Gross Margin | 53.66% | 67.31% | 56.38% | 43.90% | 53.62% | 60.27% |
Operating Margin | -161.98% | -131.52% | -218.10% | -110.96% | -77.02% | -232.97% |
Profit Margin | -191.77% | -152.12% | -223.23% | -114.74% | -84.47% | -232.87% |
Free Cash Flow Margin | - | - | -139.66% | -92.82% | -92.17% | -137.04% |
EBITDA | -15.81 | -17.52 | -56.4 | -39.62 | -32.91 | -49.61 |
EBITDA Margin | -144.33% | -118.46% | -209.72% | -106.75% | -75.41% | -156.78% |
D&A For EBITDA | 1.93 | 1.93 | 2.25 | 1.56 | 0.7 | 24.11 |
EBIT | -17.74 | -19.45 | -58.65 | -41.19 | -33.61 | -73.72 |
EBIT Margin | -161.98% | -131.52% | -218.10% | -110.96% | -77.02% | -232.97% |
Revenue as Reported | 22.92 | 26.75 | 27.62 | 38.27 | 46.4 | 32.27 |